[go: up one dir, main page]

WO2025032068A1 - Production de propylène dans des cyanobactéries - Google Patents

Production de propylène dans des cyanobactéries Download PDF

Info

Publication number
WO2025032068A1
WO2025032068A1 PCT/EP2024/072195 EP2024072195W WO2025032068A1 WO 2025032068 A1 WO2025032068 A1 WO 2025032068A1 EP 2024072195 W EP2024072195 W EP 2024072195W WO 2025032068 A1 WO2025032068 A1 WO 2025032068A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
sequence
cell according
propylene
cyanobacterial cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/072195
Other languages
English (en)
Inventor
Daniel ANTÓN GARCÍA
Aniek Doreen VAN DER WOUDE
Danuta KACZMARZYK
Dennis Kevin DIENST
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHOTANOL BV
Original Assignee
PHOTANOL BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHOTANOL BV filed Critical PHOTANOL BV
Publication of WO2025032068A1 publication Critical patent/WO2025032068A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
    • C12P5/02—Preparation of hydrocarbons or halogenated hydrocarbons acyclic
    • C12P5/026—Unsaturated compounds, i.e. alkenes, alkynes or allenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
    • C12Y103/01038—Trans-2-enoyl-CoA reductase (NADPH) (1.3.1.38)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01019—Phosphate butyryltransferase (2.3.1.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/02—Phosphotransferases with a carboxy group as acceptor (2.7.2)
    • C12Y207/02007—Butyrate kinase (2.7.2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01032—Phosphoenolpyruvate carboxykinase (GTP) (4.1.1.32)

Definitions

  • the present invention relates to the field of biochemistry, specifically to a process for producing propylene and to a cyanobacterial cell for the production of propylene.
  • Propylene (or propene) is a colourless, flammable, gaseous hydrocarbon. Propylene is the second largest-volume chemical produced globally. It is an important raw material for the production of polymers, polymer intermediates and organic chemicals such as polypropylene, acrylonitrile, propylene oxide, and oxo alcohols, as well as for a large variety of industrial products.
  • Propylene is produced primarily as a by-product of petroleum refining and of ethylene production by steam cracking of hydrocarbon feedstocks.
  • Typical hydrocarbon feedstocks are from non-renewable fossil fuels, such as petroleum, natural gas and to a much lesser extent coal.
  • the fast consumption of fossil fuels is making conventional propylene production methods unsuitable to meet the growing demand for propylene, therefore, the development of more efficient and economical production methods is a major concern.
  • Propylene can be also produced via direct fermentation of sugars or other feedstocks to produce the alcohols 2-propanol (isopropanol) or 1 -propanol, which is separated, purified, and then dehydrated to propylene in a second step involving metal-based catalysis.
  • PDH propane dehydrogenation
  • methanol-olefin process methanol-olefin process
  • Fischer-Tropsch olefin process Fischer-Tropsch olefin process.
  • Propylene can be also produced via direct fermentation of sugars or other feedstocks to produce the alcohols 2-propanol (isopropanol) or 1 -propanol, which is separated, purified, and then dehydrated to propylene in a second step involving metal-based catalysis.
  • Cyanobacteria have been reported for the production of various compounds.
  • W02009078712 relates to the production of butanol, ethanol, ethylene, succinate, propanol, acetone and D-lactate in cyanobacteria.
  • WO2011136639 relates to the production of L-lactate in cyanobacteria.
  • WO2014092562 relates to the production of acetoin, 2,3-butanediol and 2-butanol in cyanobacteria.
  • WO2016008883 relates to the production of various monoterpenes in cyanobacteria.
  • W02016008885 relates to the production of various sesquiterpenes in cyanobacteria. Eisenhut et al. (2008) relate to the CO2 concentrating mechanism of cyanobacteria.
  • FIG. 1 Western Blotting for OleT-BM3R & OleTje.
  • Positive controls of the genes expressed in E coli were included for reference.
  • FIG. 4 Butyrate feeding to cyanobacteria for propylene production using OleT-BM3R. Propylene formation in vivo, as described in Example 5, of a Synechocystis strain expressing OleT- BM3R with supplemented butyrate (second), and a propylene standard sample (first) measured using GC-FID. Negative control of a Synechocystis expressing OleT-BM3R without supplemented butyrate (third). Negative control of a Synechocystis not expressing OleT-BM3R with supplemented butyrate (fourth).
  • propylene can conveniently be produced from CO2 and light in a cyanobacterial cell.
  • the inventors of the present invention have arrived at a scalable process for the production of propylene.
  • the biosynthesis of propylene according to the present invention is based on direct conversion of CO2 and light, using a photosynthetic organism by directing the metabolism of said photosynthetic organism towards butyrate formation and using the synthetic oxidative decarboxylase enzyme OleTjE for the formation of propylene, using O2 as the oxidant and NADPH as an electron donor ( Figure 1).
  • the fatty acid decarboxylase OleTjE (from Jeotgalicoccus sp. ATCC 8456) has been shown to be functional as a catalyst for the production of linear a-alkenes, but it originally uses H2O2 as electron/oxygen donor (see, for example, Bauer et al. Production of Propene from n-Butanol: A Three- Step Cascade Utilizing the Cytochrome P450 Fatty Acid Decarboxylase OleTjE. Chembiochem 21 , 3273-3281).
  • Bauer ef al. describes the use of OleT for the production of propene, but in an enzymatic catalysis reaction feeding butanol.
  • OleT-BM3R Fusing the decarboxylase OleTjE and the reductase domain of P450BM3 creates a self-sufficient protein, OleT-BM3R, which is able to efficiently catalyse oxidative decarboxylation of carboxylic acids into linear a-olefins (see Lu etal. An Engineered Self-Sufficient Biocatalyst Enables Scalable Production of Linear a-Olefins from Carboxylic Acids. ACS CataL 8, 2018, 5794-5798).
  • the present invention combines metabolic properties of photoautotrophic and chemoorganotrophic microorganisms and is based on the employment of recombinant oxyphototrophs with high rates of conversion of Calvin cycle intermediates to a fermentative end product. Its beauty resides in the fact that its core chemical reactions use carbon dioxide as the sole carbon-containing precursor and light (preferably sunlight), as the sole energy source, to drive carbon dioxide reduction. Moreover, the cyanobacterial cell factory is more suitable for production of propylene than other microorganism used in fermentation processes such as E. coli, since the abundantly available co-factor in the cyanobacterial cell is NADPH, rather than NADH in most chemotrophic organisms used for fermentation.
  • electrons can be derived directly from photosynthesis through the endogenous ferredoxins.
  • Production may be controlled by a nutrient- or light-sensitive promoter.
  • a nutrient-sensitive promoter Using a nutrient-sensitive promoter, production is controlled by a medium component and can start at the most appropriate time, such as at the highest possible cell density.
  • a light-mediated promoter is controlled by light intensity.
  • organisms are substrate (e.g., crops in ethanol production) or product (e.g., microalgae as biodiesel), here microorganisms are used as highly specialized catalysts for the conversion of carbon dioxide as a substrate to a valuable end product.
  • the present invention relates to a cyanobacterial cell capable of expressing, preferably expressing, at least one heterologous functional enzyme, wherein the at least one functional enzyme is an oxidative decarboxylase.
  • Said cyanobacterial cell is herein further referred to as a cyanobacterial cell according to the invention or to the present invention.
  • the cyanobacterial cell is preferably capable of producing propylene, more preferably producing propylene.
  • the oxidative decarboxylase may be a cytochrome P450 enzyme.
  • the oxidative decarboxylase preferably is an OleT decarboxylase.
  • the OleT decarboxylase preferably is from Jeotgalicoccus sp. ATCC 8456.
  • the OleT decarboxylase may be linked to a redox partner.
  • the OleT decarboxylase is linked to a heterologous redox partner, such as BM3R or RhFRED.
  • the OleT decarboxylase may be linked (coupled) to the endogenous ferredoxin, receiving electrons directly from photosynthesis.
  • At least one further endogenous or heterologous functional enzyme may be present and may be selected from the group consisting:
  • a dehydratase a reductase, an esterase, and a decarboxylase; preferably a 3-hydroxbutyryl- CoA dehydratase (crotonase), a trans-enoyl-coA reductase and/or a thioesterase; or
  • a malonyl CoA-ACP transacylase (fabD), p-ketoacyl-ACP synthase III (fabH), p-ketoacyl- ACP reductase (fabG), p-hydroxyacyl-ACP dehydratase (fabZ), enoyl-ACP reductase (fabl) and a thioesterase (TE); and optionally, an acetyl-CoA acetyltransferase (phaA), ketoacyl-ACP synthase III (NphT7) and an acetoacetyl-CoA reductase (phaB).
  • a preferred 3-hydroxbutyryl-CoA dehydratase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.
  • a preferred 3-hydroxbutyryl-CoA dehydratase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 6.
  • a preferred 3-hydroxbutyryl-CoA dehydratase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 7.
  • a preferred 3-hydroxbutyryl-CoA dehydratase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 8.
  • a preferred a trans-enoyl-coA reductase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO:9, and SEQ ID NO: 10.
  • a preferred a trans-enoyl-coA reductase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO:9.
  • a preferred a trans-enoyl-coA reductase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 10.
  • a preferred thioesterase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 13, 14, 15, 16, 17, 18, 19, and SEQ ID NO: 20.
  • a preferred thioesterase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 13.
  • a preferred thioesterase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 14.
  • a preferred thioesterase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 15.
  • a preferred thioesterase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 16.
  • a preferred thioesterase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 1
  • a preferred thioesterase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 18.
  • a preferred thioesterase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 19.
  • a preferred thioesterase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 20.
  • a preferred butyrate kinase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 25, 26, 27, and SEQ ID NO: 28.
  • a preferred butyrate kinase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 25.
  • a preferred butyrate kinase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 26.
  • a preferred butyrate kinase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 27.
  • a preferred butyrate kinase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 28.
  • a preferred CoA-ACP transacylase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 29.
  • a preferred p-ketoacyl-ACP synthase III comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 30.
  • a preferred p-ketoacyl-ACP reductase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 31 .
  • a preferred P-hydroxyacyl-ACP dehydratase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 32.
  • a preferred thioesterase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 25, 26, 27, and SEQ ID NO: 28.
  • a preferred butyrate kinase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 34, 35, 36, and SEQ ID NO: 37.
  • a preferred butyrate kinase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 34.
  • a preferred butyrate kinase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 35.
  • a preferred butyrate kinase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 36.
  • a preferred butyrate kinase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 37.
  • a preferred acetyl-CoA acetyltransferase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 1 , and SEQ ID NO: 2.
  • a preferred acetyl-CoA acetyltransferase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 1 .
  • a preferred acetyl-CoA acetyltransferase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 2.
  • a preferred ketoacyl-ACP synthase III comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 3.
  • a preferred acetoacetyl-CoA reductase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 4, and SEQ ID NO: 5.
  • a preferred acetoacetyl-CoA reductase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 4.
  • a preferred acetoacetyl-CoA reductase comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with SEQ ID NO: 5.
  • the at least one further functional enzyme may be one selected from the enzymes listed in Table 1 below.
  • the oxidative decarboxylase preferably comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 54 and SEQ ID NO: 57.
  • the oxidative decarboxylase preferably comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 54.
  • the oxidative decarboxylase preferably comprises or consists of a polypeptide that has an amino acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 57.
  • the oxidative decarboxylase is preferably encoded by a polynucleotide that has an nucleic acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 55, and SEQ ID NO: 56.
  • the oxidative decarboxylase is preferably encoded by a polynucleotide that has an nucleic acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 52.
  • the oxidative decarboxylase is preferably encoded by a polynucleotide that has an nucleic acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 53.
  • the oxidative decarboxylase is preferably encoded by a polynucleotide that has an nucleic acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 55.
  • the oxidative decarboxylase is preferably encoded by a polynucleotide that has an nucleic acid sequence with at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 56.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, and SEQ ID NO: 49.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 38.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 39.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 40.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 41 .
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 42.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 43.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 44.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 45.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 46.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 47.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 48.
  • the polynucleotide encoding the oxidative decarboxylase may be under the control of a constitutive promoter, wherein the constitutive promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the sequence as set forward in SEQ ID NO: 49.
  • the polynucleotide encoding the oxidative decarboxylase may be underthe control of a nutrient-regulated promoter, wherein preferably a nutrient-regulated promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity with SEQ ID NO: 50, or with SEQ ID NO: 51 .
  • the polynucleotide encoding the oxidative decarboxylase may be underthe control of a nutrient-regulated promoter, wherein preferably a nutrient-regulated promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity with SEQ ID NO: 50.
  • the polynucleotide encoding the oxidative decarboxylase may be underthe control of a nutrient-regulated promoter, wherein preferably a nutrient-regulated promoter has at least 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity with SEQ ID NO: 51 .
  • the expression of said polynucleotide or polynucleotides preferably confers to the cell the ability to convert a butyrate intermediate into propylene.
  • a preferred butyrate intermediate is butyric acid.
  • the cyanobacterial cell is capable of producing and preferably produces at least 1 .0 ug propylene per liter of culture volume when cultured under conditions conducive to the production of propylene.
  • the culture conditions include culturing in the presence of sunlight and feeding carbon dioxide for at least 1 day.
  • the propylene produced within the cyanobacterial cell according to the invention may be present in a gas mixture.
  • Assays for the detection of propylene are, but not limited to Gas Chromatography (GC) or Gas Chromatography-Mass Spectrometry (GC-MS).
  • a preferred assay for the detection of propylene is Gas Chromatography (GC).
  • a detectable amount for propylene is preferably at least 1 .0 pg per liter culture volume under said culture conditions and using GC.
  • a detectable amount (per liter culture volume) is at least 2.0pg.
  • a cyanobacterial cell according to the present invention comprises at least one nucleic acid molecule comprising or consisting of a polynucleotide encoding at least one of the at least one functional enzyme as defined herein above.
  • a preferred cyanobacterial cell according to the invention comprises at least one nucleic acid molecule comprising or consisting of a polynucleotide encoding at least one of the at least one functional enzyme as defined herein above.
  • each encoding polynucleotide may be present on a separate nucleic acid molecule.
  • two or more encoding polynucleotides may be present on a single nucleic acid molecule.
  • a preferred cyanobacterial cell according to the invention is a cyanobacterial cell wherein the at least one functional enzyme is encoded by a nucleic acid molecule comprising or consisting of a polynucleotide wherein said nucleic acid molecule is preferably present in the cyanobacterial cell as an episomal entity, preferably said episomal entity is a plasmid, more preferably a self-replicating plasmid.
  • the episomal entity and plasmid can be any episomal entity and plasmid known to the person skilled in the art or can be based on any episomal entity and plasmid known to the person skilled in the art and modified to comprise any nucleic acid and/or polynucleotide described herein.
  • Another preferred cyanobacterial cell according to the invention is a cyanobacterial cell wherein the at least one functional enzyme is encoded by a nucleic acid molecule comprising or consisting of a polynucleotide wherein said nucleic acid molecule is preferably integrated in the cyanobacterial genome, preferably via homologous recombination.
  • a cyanobacterial cell according to the present invention may comprise a single copy but may also comprise multiple copies of a nucleic acid molecule comprising or consisting of an polynucleotide encoding a functional enzyme as defined herein above.
  • a preferred cyanobacterial cell according to the present invention is a cyanobacterial cell, wherein a polynucleotide encoding the at least one functional enzyme is under control of a regulatory system which responds to a change in the concentration of a nutrient when culturing said cyanobacterial cell.
  • a promoter that may be used for the expression of a polynucleotide encoding the at least one functional enzyme may be foreign to the polynucleotide, i.e. a promoter that is heterologous to the polynucleotide encoding the at least one functional enzyme to which it is operably linked.
  • a promoter preferably is heterologous to the polynucleotide to which it is operably linked, it is also possible that a promoter is native to the cyanobacterial cell according to the present invention.
  • a heterologous (to the nucleotide sequence) promoter is capable of producing a higher steady state level of a transcript comprising a coding sequence (or is capable of producing more transcript molecules, i.e.
  • a suitable promoter in this context includes both a constitutive and an inducible natural promoter as well as an engineered promoter.
  • a promoter used in a cyanobacterial cell according to the present invention may be modified, if desired, to affect its control characteristics.
  • a promoter used in a cyanobacterial cell according to the present invention may be selected from, but not limited to promoters listed in Table 2 below or a functional fragment thereof. Table 2. Promoters
  • a preferred promoter for constitutive expression is a Ptrc.
  • the Ptrc promoter is a synthetic promoter, which is constructed as a chimera of the E. coli trp operon and /acUV5 promoters (Brosius et al, J Biol Chem 1985).
  • the promoter is thus regulated by the Lac repressor, Lacl.
  • the Lacl regulated repression and induction does not function efficiently, but the Ptrc promoter does show high constitutive expression levels in the absence of Lacl (Huang H-H, Camsund D, Lindblad P, Heidorn T: Design and characterization of molecular tools for a Synthetic Biology approach towards developing cyanobacterial biotechnology. Nucleic Acids Res 2010, 38:2577-2593).
  • the cyanobacterial cell according to the present invention can conveniently be used for the production of propylene.
  • the present invention relates to a process for producing propylene comprising culturing a cyanobacterial cell according to the present invention, preferably a cyanobacterial cell as defined in the first aspect of the present invention, under conditions conducive to the production of propylene-containing gas mixture and, optionally, separating propylene from the gas mixture.
  • the culture conditions may comprise feeding carbon dioxide to the culture of cyanobacterial cells and/or subjecting the culture to light. In the embodiments herein, the culture conditions may further comprise feeding butyric acid to the culture of cyanobacterial cells.
  • carbon dioxide is fed to the culture of cyanobacterial cells.
  • the culture of cyanobacterial cells is subjected to light.
  • carbon dioxide is fed to the culture of cyanobacterial cells and the culture of cyanobacterial cells is subjected to light.
  • a preferred natural light is sunlight.
  • Daylight (or sunlight) may have an intensity ranged between approximately 500 and approximately 1500 pEinstein/m 2/s.
  • the light used may be sunlight (direct or indirect) and/or may be artificial light.
  • Such artificial light may have an intensity ranged between approximately 70 and approximately 800 pEinstein/m 2/s.
  • the cells are continuously under the light conditions as specified herein above.
  • the cells may also be exposed to high light intensities (such as e.g. daylight/sunlight) as defined herein above for a certain amount of time, after which the cells are exposed to a lower light intensity as defined elsewhere herein for a certain amount of time, and optionally this cycle is repeated.
  • the cycle is the day/night cycle.
  • propylene is separated from the gas mixture. This may be realized continuously with the production process or subsequently to it. Separation may be based on any separation method known to the person skilled in the art.
  • the present invention relates to propylene, obtainable by a process according to the present invention as described above.
  • oxidative decarboxylase as an enzyme from the family of lyases and able to catalyze the loss of carbon dioxide from a carboxylic acid by electron oxidation which results in propylene formation.
  • a cyanobacterium In the context of all embodiments of the present invention, the terms “a cyanobacterium”, “a cyanobacterium cell” and “a cyanobacterial cell” are used interchangeably and refer to a blue-green algae, a photosynthetic unicellular microorganism.
  • cyanobacteria include the genera Aphanocapsa, Anabaena, Nostoc, Oscillatoria, Synechococcus, Synechocystis, Gloeocapsa, Agmenellum, Scytonema, Mastigocladus, Arthrosprira, Haplosiphon.
  • a cyanobacterial cell according to the present invention may be or may be derived from a Synechococcus, preferably Synechococcus elongatus PCC 7942, Synechococcus PCC7002, Synechococcus PCC11901, or from a Synechocystis, preferably a Synechocystis PCC 6803.
  • a preferred order of cyanobacteria is Chroococcales.
  • a preferred cyanobacterium genus is Synechocystis.
  • Another preferred cyanobacterium genus is Synechococcus.
  • a more preferred species are Synechococcus elongatus PCC 7942 and Synechocystis PCC 6803 species.
  • the Synechocystis is a Pasteur Culture Collection (PCC) 6803 Synechocystis, which is a publicly available strain via ATCC for example.
  • PCC 6803 has been stored at ATCC under ATCC27184.
  • the phototrophic Synechocystis PCC 6803 is a fast growing cyanobacterium with no specific nutritional demands.
  • Synechocystis sp. PCC 6803 can grow in the absence of photosynthesis if a suitable fixed-carbon source such as glucose is provided. Perhaps most significantly, Synechocystis sp. PCC 6803 was the first photosynthetic organism for which the entire genome sequence was determined (available via the internet world wide web at kazusa.or.jp/cyano/cyano). In addition, an efficient gene deletion strategy (Shestakov SV et al., 2002; and Nakamura Y et al., 1999) is available for Synechocystis sp. PCC 6803, and this organism is furthermore easily transformable via homologous recombination (Grigirieva GA et aL, 1982).
  • Capable of producing propylene preferably means herein that detectable amounts of propylene can be detected in a culture of a cyanobacterial cell according to the present invention cultured, under conditions conducive to the production of propylene, preferably in the presence of light and dissolved carbon dioxide and/or bicarbonate ions, during at least 1 day using a suitable assay for detecting propylene.
  • a preferred concentration of said dissolved carbon dioxide and/or bicarbonate ions is, the natural occurring concentration at neutral to alkaline conditions (pH 7 to 9) being approximately 1 mM. This is equivalent to 0.035% of carbon dioxide in ambient air. A more preferred concentration of carbon dioxide and/or bicarbonate ions is higher than this natural occurring concentration.
  • the concentration of bicarbonate ions is at least 0.5 mM, 0.6 mM, 0.7 mM, 0.8 mM, 0.9 mM, 1 mM, 2 mM, 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 60 mM, 70 mM, 80 mM, 90 mM or 100 mM... up to 200mM.
  • a preferred method to increase the carbon dioxide and/or bicarbonate ions in solution is by enrichment with carbon dioxide, preferably waste carbon dioxide from industrial plants, sparged into the culture broth.
  • the concentration of carbon dioxide is preferably increased to at least 0.04%, 0.05%, 0.1%, 0.15%, 0.2%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5%.
  • sequence identity in the context of amino acid- or nucleic acid-sequence is herein defined as a relationship between two or more amino acid (peptide, polypeptide, or protein) sequences or two or more nucleic acid (nucleotide, polynucleotide) sequences, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between amino acid or nucleotide sequences, as the case may be, as determined by the match between strings of such sequences.
  • sequence identity with a particular sequence preferably means sequence identity over the entire length of said particular polypeptide or polynucleotide sequence.
  • the sequence information as provided herein should not be so narrowly construed as to require inclusion of erroneously identified bases. The skilled person is capable of identifying such erroneously identified bases and knows how to correct for such errors.
  • Similarity between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one peptide or polypeptide to the sequence of a second peptide or polypeptide. In a preferred embodiment, identity or similarity is calculated over the whole SEQ ID NO as identified herein. "Identity” and “similarity” can be readily calculated by known methods, including but not limited to those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H.
  • Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include e.g. the GCG program package (Devereux, J., et al., Nucleic Acids Research 12 (1): 387 (1984)), BestFit, BLASTP, BLASTN, and FASTA (Altschul, S. F. et al., J. Mol. Biol. 215:403- 410 (1990).
  • the BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et aL, NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et aL, J. Mol. Biol. 215:403-410 (1990).
  • the well-known Smith Waterman algorithm may also be used to determine identity.
  • Preferred parameters for polypeptide sequence comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992); Gap Penalty: 12; and Gap Length Penalty: 4.
  • a program useful with these parameters is publicly available as the "Ogap" program from Genetics Computer Group, located in Madison, WL
  • the aforementioned parameters are the default parameters for amino acid comparisons (along with no penalty for end gaps).
  • amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine.
  • Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alaninevaline, and asparagine-glutamine.
  • Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place.
  • the amino acid change is conservative.
  • Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gin or his; Asp to glu; Cys to ser or ala; Gin to asn; Glu to asp; Gly to pro; His to asn or gin; lie to leu or val; Leu to ile or val; Lys to arg; gin or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
  • a polynucleotide is represented by a nucleotide sequence.
  • a polypeptide is represented by an amino acid sequence.
  • a nucleic acid construct is defined as a polynucleotide which is isolated from a naturally occurring gene or which has been modified to contain segments of polynucleotides which are combined or juxtaposed in a manner which would not otherwise exist in nature.
  • a polynucleotide present in a nucleic acid construct is operably linked to one or more control sequences, which direct the production or expression of said peptide or polypeptide in a cell or in a subject.
  • Polynucleotides described herein may be native or may be codon optimized.
  • Codon optimization adapts the codon usage for an encoded polypeptide towards the codon bias of the organism where the polypeptide is to be produced in. Codon optimization generally helps to increase the production level of the encoded polypeptide in the host cell, such as in the preferred host herein: Cyanobacterium Synechocystis. Many algorithms are available to the person skilled in the art for codon optimization. A preferred method is the “guided random method based on a Monte Carlo alogorithm available via the internet world wide web genomes.urv.es/OPTIMIZER/ (P. Puigbo, E. Guzman, A. Romeu, and S. Garcia-Vallve. Nucleic Acids Res. 2007 July; 35: W126-W131).
  • heterologous is one that is not naturally found.
  • heterologous may mean “recombinant”.
  • Recombinant refers to a genetic entity distinct from that generally found in nature. As applied to a nucleotide sequence or nucleic acid molecule, this means that said nucleotide sequence or nucleic acid molecule is the product of various combinations of cloning, restriction and/or ligation steps, and other procedures that result in the production of a construct that is distinct from a sequence or molecule found in nature.
  • “Operably linked” is defined herein as a configuration in which a control sequence is appropriately placed at a position relative to the nucleotide sequence coding for the polypeptide of the invention such that the control sequence directs the production/expression of the peptide or polypeptide of the invention in a cell and/or in a subject. “Operably linked” may also be used for defining a configuration in which a sequence is appropriately placed at a position relative to another sequence coding for a functional domain such that a chimeric polypeptide is encoded in a cell and/or in a subject.
  • Expression will be understood to include any step involved in the production of the peptide or polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post- translational modification and secretion.
  • promoter refers to a nucleic acid fragment that functions to control the transcription of one or more nucleic acid molecules, located upstream with respect to the direction of transcription of the transcription initiation site of the nucleic acid molecule, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter.
  • a “constitutive” promoter is a promoter that is active under most environmental and developmental conditions.
  • An “inducible” promoter is a promoter that is active under environmental or developmental regulation.
  • the cell can be transformed with a nucleic acid or nucleic acid construct described herein by any method known to the person skilled in the art.
  • Such methods are e.g. known from standard handbooks, such as Sambrook and Russel (2001) “Molecular Cloning: A Laboratory Manual (3 rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, or F. Ausubel et al, eds., “Current protocols in molecular biology”, Green Publishing and Wiley Interscience, New York (1987).
  • Methods for transformation and genetic modification of cyanobacterial cells are known from e.g. U.S. Pat. No. 6,699,696 or U.S. Pat. No. 4,778,759.
  • a selectable marker may be present in the nucleic acid construct comprising a polynucleotide encoding the enzyme.
  • the term “marker” refers herein to a gene encoding a trait or a phenotype which permits the selection of, or the screening for, a cyanobacterial cell containing the marker.
  • a marker gene may be an antibiotic resistance gene whereby the appropriate antibiotic can be used to select for transformed cells from among cells that are not transformed.
  • markers include, but are not limited to, aminoglycoside phosphotransferases for kanamycin and streptomycin/spectinomycin, and chloramphenicol acetyltransferase
  • a non-antibiotic resistance marker may be used, such as an auxotrophic marker (URA3, TRP1 , LEU2).
  • the cyanobacterial cell e.g. transformed with a nucleic acid construct, may be marker gene free. Methods for constructing recombinant marker gene free microbial host cells are described in (Cheah et al., 2013) and are based on the use of bidirectional markers.
  • a screenable marker such as Green Fluorescent Protein, lacZ, luciferase, chloramphenicol acetyltransferase, beta-glucuronidase may be incorporated into a nucleic acid construct according to the invention allowing to screen for transformed cells.
  • nucleic acid constructs include, but are not limited to, one or more leader sequences, enhancers, integration factors, and/or reporter genes, intron sequences, centromers, telomers and/or matrix attachment (MAR) sequences.
  • a nucleic acid construct according to the invention can be provided in a manner known per se, which generally involves techniques such as restricting and linking nucleic acids/nucleic acid sequences, for which reference is made to the standard handbooks, such as Sambrook and Russel (2001) “Molecular Cloning: A Laboratory Manual (3 rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press.
  • the word “about” or “approximately” when used in association with a numerical value preferably means that the value may be the given value (of 10) more or less 0.1 % of the value.
  • sequence information as provided herein should not be so narrowly construed as to require inclusion of erroneously identified bases.
  • the skilled person is capable of identifying such erroneously identified bases and knows how to correct for such errors.
  • sequence errors the sequence of the enzymes obtainable by expression of the genes as represented by SEQ ID Nos: 52, 53, 55 and 56 containing the enzyme encoding polynucleotide sequences should prevail.
  • Escherichia coli strains XL-1 blue (Stratagene), Turbo (NEB) or CopyCutter EPI400 (Epicentre biotechnologies) were used for plasmid amplification and manipulation, grown at 37°C in Lysogeny Broth (LB) or on LB agar.
  • Escherichia coli strains BL21 (DE3) were used for expression of recombinant proteins, grown at 37 °C in LB or on LB agar.
  • the following antibiotics were used: ampicillin (100 pg/ml), kanamycin (20 or 50 pg/ml, for Synechocystis and E. coli, respectively), spectinomycin (25 or 50 pg/ml, for Synechocystis and E.
  • Restriction endonucleases were purchased from Thermo Scientific. Cloning was performed in E. coli using CaCh-competent XL1-blue, Turbo or CopyCutter EPI400 cells, according to manufacturer protocol.
  • the nucleotide sequence encoding OleT and OleT-BM3R were synthesized using the native nucleotide sequence or with codon-optimization (IDT) [SEQ ID NOs: 52, 53, 55, 56], and inserted with either a Ptrcl [SEQ ID NO: 45] or PcpcBA promoter [SEQ ID NO: 42] into the broad host range RSF1010 derivative plasmid pAVO+ (van der Woude et aL, 2016).
  • An N-terminal His10-tag [SEQ ID NO: 58] and a linker sequence were inserted between the promoter and the gene to allow for protein detection using Western Blotting.
  • the resulting constructs were introduced through conjugation into a markerless Synechocystis strain with a PhaEC deletion.
  • nucleotide sequences encoding phaJ, TER and TE [SEQ ID NOs: 6, 9, 10, 15, 19, 34, 35, 36, 37] were synthesized using the native nucleotide sequence or with codon-optimization, and inserted with a Ptrcl promoter [SEQ ID NO: 45] into the broad host range RSF1010 derivative plasmid pAVO+ (van der Woude et aL, 2016). The resulting constructs were introduced through conjugation into a markerless Synechocystis strain with a phaEC deletion.
  • GC-FID analysis was carried out using a Shimadzu GC-2010 system equipped with a Rt-Q- BOND 30 m x 0.32 mm column and a HS-20 headspace autosampler. After equilibration at 60 °C for 2 minutes in the autosampler, the samples were pressurized to 100 kPa during 1 minute, and further equilibrated for 0.5 min. The headspace was then drawn to a transfer line heated at 150 °C for 0.5 minutes, and after 0.1 minutes, the samples were injected during 1 minute with a 1 :20 split mode.
  • the carrier gas was H 2 with a column flow of 2.5 mL/min in a flow control mode using constant linear velocity.
  • the FID detector temperature was set at 260 °C.
  • the column was heated from 40 °C to 90 °C at a rate of 21 °C min -1 , after which heating proceeded at a rate of 10 °C min -1 until a temperature of 120 °C was reached and kept constant for 2 min.
  • Samples for HPLC were analysed with a Shimadzu LC-20AT Prominence system equipped with a UV-vis detector (Shimadzu SPD-20A) set at 210 nm and a refractive index detector (Shimadzu RID- 20A).
  • Samples and standards (15 pL) were injected using an autosampler (Shimadzu SIL-20AC) onto a 300x 7.8 mm column (Ion exclusion Rezex ROA-Organic Acid H+(8%)) purchased from Phenomenex.
  • the mobile phase comprised 5 mM sulfuric acid with a total flow rate of 0.9 ml min -1 at 55 °C.
  • Synechocystis cells expressing OleT-BM3R were cultivated as described above, followed by pelleting of 50 OD units and discarding of the supernatant. The pellet was kept at -80 °C until further use.
  • the cells were resuspended in 600 pL of lysation buffer (100 mM Tris-HCI, pH 7.5; 10% glycerol, complete Protease Inhibitor Cocktail EDTA-free) and lysed by bead beating (3x 20 sec 6000 rpm). Soluble lysate was obtained by centrifuging for 30 minutes at 15 000 rpm.
  • BCA bicinchoninic acid
  • S/D buffer (5X) was prepared containing final concentrations of 250 mM Tris-HCI (pH 6.8), 500 mM dithiothreitol (DTT), 10% sodium dodecyl sulphate (SDS), 25 mM EDTA and 50% in distilled water.
  • MOPS (Genscript) buffer was added to deionized water. Precast gels from Genscript, with Express Plus gradient of 8-16% were used. Before loading, protein samples (3.3 pg) were mixed with S/D buffer and boiled at 90 °C for 10 minutes.
  • Blotting transfer buffer was prepared from 3.0 g Tris base, 4.1 g Bicine 100 mL of methanol and 900 mL of water. The blotting chamber ran for 350 mA for 90 minutes or 50 mA overnight.
  • the nitrocellulose membrane was taken out from the sandwich and shaken in 5% milkpowder (low fat) PBS-T blocking buffer (25mL) for 60 minutes at room temperature.
  • 10X PBS-T was previously prepared in a 1 L volume which contained 4.28 g sodium phosphate monobasic monohydrate, 10.5 g sodium phosphate dibasic dihydrate, 90 g sodium chloride, 0.1 g merthiolate, 7 mL Tween and as remainder MilliQ water. The pH was set to 7.2 with NaOH (12g/50mL). Afterwards the primary antibody was added in a new 5% milkpowder PBS-T solution. For proteins with the histidine tag, Sigma antibody (A7058, 1 :10.000 dilution) was used. Afterwards the gel was washed three times in PBS-T for 10 minutes.
  • Example 4 Enzyme assays with OleT-BM3R lysates with supplemented butyrate and NADPH Synechocystis cells expressing OleT-BM3R were cultivated as described above, followed by pelleting of 50 OD units and discarding of the supernatant. The pellet was kept at -80 °C until further use. The cells were resuspended in 600 pL of lysation buffer (100 mM Tris-HCI, pH 7.5; 10% glycerol, complete Protease Inhibitor Cocktail EDTA-free) and lysed by bead beating (3x 20 sec 6000 rpm). Soluble lysate was obtained by centrifuging for 30 minutes at 15 000 rpm.
  • lysation buffer 100 mM Tris-HCI, pH 7.5; 10% glycerol, complete Protease Inhibitor Cocktail EDTA-free
  • the buffer employed for the enzyme consisted of Tris-HCI (100 mM, pH 7.5) and KCI (300 mM) in glycerol (20%). After addition of the required co-factors (butyrate, 10 mM; NADPH, 10 mM) the pH was re-adjusted to 7.5. Buffer (2.9 mL) and soluble lysate (100 pL) were mixed in a closed-vial reactor and incubated overnight at 22 °C, shaking 110 rpm. The headspace was sampled for propylene analysis via GC-FID ( Figure 3).
  • Strains expressing heterologous phaJ, TER, TE and OleT-BM3R are cultivated as described above. During the course of the 8-day experiment, cultures at different cell densities are supplemented with additional NaHCOs (100 mM) and transferred to a closed reactor. The cultures are further incubated during 96 h, followed by sampling of the headspace for propylene analysis via GC-FID and butyrate quantification via HPLC. An amount of 1 .8 pg propylene per liter of culture volume is measured.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un procédé de production de propylène et une cellule cyanobactérienne pour la production de propylène.
PCT/EP2024/072195 2023-08-07 2024-08-06 Production de propylène dans des cyanobactéries Pending WO2025032068A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23190066 2023-08-07
EP23190066.3 2023-08-07

Publications (1)

Publication Number Publication Date
WO2025032068A1 true WO2025032068A1 (fr) 2025-02-13

Family

ID=87557952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/072195 Pending WO2025032068A1 (fr) 2023-08-07 2024-08-06 Production de propylène dans des cyanobactéries

Country Status (1)

Country Link
WO (1) WO2025032068A1 (fr)

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778759A (en) 1982-07-09 1988-10-18 Boyce, Thompson Institute For Plant Research, Inc. Genetic engineering in cyanobacteria
US6699696B2 (en) 1997-02-19 2004-03-02 Enol Energy Inc. Genetically modified cyanobacteria for the production of ethanol, the constructs and method thereof
WO2009078712A2 (fr) 2007-12-17 2009-06-25 Universiteit Van Amsterdam Réduction de co2 générée par la lumière sur des composés organiques destinés à servir de combustibles ou de semi-produits industriels au moyen d'un organisme autotrophe contenant une cassette génétique fermentative
WO2010075483A2 (fr) * 2008-12-23 2010-07-01 Ls9, Inc. Procédés et compositions relatives à des enzymes thioestérases
US20110196180A1 (en) * 2007-12-21 2011-08-11 Ls9, Inc. Methods and compositions for producing olefins
WO2011136639A1 (fr) 2010-04-28 2011-11-03 Photanol Bv Production de l-lactate chez des cyanobactéries
WO2012175750A1 (fr) * 2011-06-24 2012-12-27 Algenol Biofuels Inc. Cyanobactéries génétiquement modifiées ne contenant pas de gène fonctionnel conférant une résistance contre les biocides et permettant de produire des composés chimiques
WO2013028792A2 (fr) * 2011-08-22 2013-02-28 Joule Unlimited Technologies, Inc. Compositions améliorées et procédés améliorés pour la biosynthèse de 1-alcènes dans des micro-organismes génétiquement modifiés
WO2013028519A1 (fr) * 2011-08-19 2013-02-28 Genomatica, Inc. Microorganismes et procédés de fabrication de 2,4-pentadiénoate, de butadiène, de propylène, de 1,3-butanediol et d'alcools associés
WO2013098267A1 (fr) * 2011-12-30 2013-07-04 Algenol Biofuels Inc. Cyanobactéries génétiquement améliorées pour la production d'un premier composé chimique présentant des promoteurs inductibles par zn2+, co2+ ou ni2+
WO2014092562A1 (fr) 2012-12-11 2014-06-19 Photanol B.V. Synthèse d'acétoïne, de 2,3-butanediol et de 2-butanol par des cyanobactéries par expression hétérologue d'une voie catabolique
US20140178973A1 (en) * 2012-12-21 2014-06-26 Algenol Biofuels Inc. Cyanobacterium sp. Host Cell and Vector for Production of Chemical Compounds in Cyanobacterial Cultures
US20150050708A1 (en) * 2013-03-15 2015-02-19 Genomatica, Inc. Microorganisms and methods for producing butadiene and related compounds by formate assimilation
WO2016008885A1 (fr) 2014-07-14 2016-01-21 Photanol B.V. Biosynthèse de sesquiterpènes dans des cyanobactéries
WO2016008883A1 (fr) 2014-07-14 2016-01-21 Photanol B.V. Biosynthèse de monoterpènes dans des cyanobactéries
WO2021168228A1 (fr) * 2020-02-21 2021-08-26 Dow Silicones Corporation Procédé de préparation de silanols avec des variants sélectifs du cytochrome p450 et composés et compositions associés

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778759A (en) 1982-07-09 1988-10-18 Boyce, Thompson Institute For Plant Research, Inc. Genetic engineering in cyanobacteria
US6699696B2 (en) 1997-02-19 2004-03-02 Enol Energy Inc. Genetically modified cyanobacteria for the production of ethanol, the constructs and method thereof
WO2009078712A2 (fr) 2007-12-17 2009-06-25 Universiteit Van Amsterdam Réduction de co2 générée par la lumière sur des composés organiques destinés à servir de combustibles ou de semi-produits industriels au moyen d'un organisme autotrophe contenant une cassette génétique fermentative
US20110196180A1 (en) * 2007-12-21 2011-08-11 Ls9, Inc. Methods and compositions for producing olefins
WO2010075483A2 (fr) * 2008-12-23 2010-07-01 Ls9, Inc. Procédés et compositions relatives à des enzymes thioestérases
WO2011136639A1 (fr) 2010-04-28 2011-11-03 Photanol Bv Production de l-lactate chez des cyanobactéries
WO2012175750A1 (fr) * 2011-06-24 2012-12-27 Algenol Biofuels Inc. Cyanobactéries génétiquement modifiées ne contenant pas de gène fonctionnel conférant une résistance contre les biocides et permettant de produire des composés chimiques
WO2013028519A1 (fr) * 2011-08-19 2013-02-28 Genomatica, Inc. Microorganismes et procédés de fabrication de 2,4-pentadiénoate, de butadiène, de propylène, de 1,3-butanediol et d'alcools associés
WO2013028792A2 (fr) * 2011-08-22 2013-02-28 Joule Unlimited Technologies, Inc. Compositions améliorées et procédés améliorés pour la biosynthèse de 1-alcènes dans des micro-organismes génétiquement modifiés
WO2013098267A1 (fr) * 2011-12-30 2013-07-04 Algenol Biofuels Inc. Cyanobactéries génétiquement améliorées pour la production d'un premier composé chimique présentant des promoteurs inductibles par zn2+, co2+ ou ni2+
WO2014092562A1 (fr) 2012-12-11 2014-06-19 Photanol B.V. Synthèse d'acétoïne, de 2,3-butanediol et de 2-butanol par des cyanobactéries par expression hétérologue d'une voie catabolique
US20140178973A1 (en) * 2012-12-21 2014-06-26 Algenol Biofuels Inc. Cyanobacterium sp. Host Cell and Vector for Production of Chemical Compounds in Cyanobacterial Cultures
US20150050708A1 (en) * 2013-03-15 2015-02-19 Genomatica, Inc. Microorganisms and methods for producing butadiene and related compounds by formate assimilation
WO2016008885A1 (fr) 2014-07-14 2016-01-21 Photanol B.V. Biosynthèse de sesquiterpènes dans des cyanobactéries
WO2016008883A1 (fr) 2014-07-14 2016-01-21 Photanol B.V. Biosynthèse de monoterpènes dans des cyanobactéries
WO2021168228A1 (fr) * 2020-02-21 2021-08-26 Dow Silicones Corporation Procédé de préparation de silanols avec des variants sélectifs du cytochrome p450 et composés et compositions associés

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
"Biocomputing: Informatics and Genome Projects", 1993, ACADEMIC PRESS
"Sequence Analysis Primer", 1991, M STOCKTON PRESS
ALTSCHUL, S. F. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
AUSUBEL ET AL.: "Current Protocols in Molecular Biology, Current Protocols", vol. 1, 2, 1994, HUMANA PRESS
BAUER ET AL.: "Production of Propene from n-Butanol: A Three-Step Cascade Utilizing the Cytochrome P450 Fatty Acid Decarboxylase OleT", CHEMBIOCHEM, vol. 21, pages 3273 - 3281
BAUER ET AL.: "Production of Propene from n-Butanol: A Three-Step Cascade Utilizing the Cytochrome P450 Fatty Acid Decarboxylase OleTJE", CHEMBIOCHEM, vol. 21, pages 3273 - 3281
BROSIUS ET AL., J BIOL CHEM, 1985
BROWN: "Molecular Biology LabFax", vol. 1, 2, 1998, ACADEMIC PRESS
CARILLO, H.LIPMAN, D., SIAM J. APPLIED MATH., vol. 48, 1988, pages 1073
CHEAH ET AL., BIOTECHNOL PROG, vol. 29, 2013, pages 23 - 30
CHOI YUN-NAM ET AL: "Acetyl-CoA-derived biofuel and biochemical production in cyanobacteria: a mini review", JOURNAL OF APPLIED PHYCOLOGY, KLUWER, DORDRECHT, NL, vol. 32, no. 3, 21 May 2020 (2020-05-21), pages 1643 - 1653, XP037165766, ISSN: 0921-8971, [retrieved on 20200521], DOI: 10.1007/S10811-020-02128-X *
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, no. 1, 1984, pages 387
FANG BO ET AL: "Mutagenesis and redox partners analysis of the P450 fatty acid decarboxylase OleTJE", SCIENTIFIC REPORTS, vol. 7, no. 1, 9 March 2017 (2017-03-09), US, XP093220662, ISSN: 2045-2322, Retrieved from the Internet <URL:https://www.nature.com/articles/srep44258.pdf> DOI: 10.1038/srep44258 *
GRIGIRIEVA GA ET AL., FEMS MICROBIOL. LETT., vol. 13, 1982, pages 367 - 370
HENTIKOFFHENTIKOFF, PROC. NATL. ACAD. SCI. USA., vol. 89, 1992, pages 10915 - 10919
HUANG H-H, CAMSUND D, LINDBLAD P, HEIDORN T: "Design and characterization of molecular tools for a Synthetic Biology approach towards developing cyanobacterial biotechnology", ACIDS RES, vol. 38, 2010, pages 2577 - 2593, XP055137210, DOI: 10.1093/nar/gkq164
HUANG H-HCAMSUND DLINDBLAD PHEIDORN T: "Design and characterization of molecular tools for a Synthetic Biology approach towards developing cyanobacterial biotechnology", NUCLEIC ACIDS RES, vol. 38, 2010, pages 2577 - 2593, XP055137210, DOI: 10.1093/nar/gkq164
LAI ET AL.: "Photoautotrophic synthesis of butyrate by metabolically engineered cyanobacteria", BIOTECHNOLOGY AND BIOENGINEERING, vol. 116, no. 4, April 2019 (2019-04-01), pages 893 - 903, XP071032940, DOI: 10.1002/bit.26903
LIU KUN ET AL: "Biosynthesis of fatty acid-derived hydrocarbons: perspectives on enzymology and enzyme engineering", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 62, 17 September 2019 (2019-09-17), pages 7 - 14, XP086153647, ISSN: 0958-1669, [retrieved on 20190917], DOI: 10.1016/J.COPBIO.2019.07.005 *
LU ET AL.: "An Engineered Self-Sufficient Biocatalyst Enables Scalable Production of Linear a-Olefins from Carboxylic Acids", ACS CATAL., vol. 8, 2018, pages 5794 - 5798, XP093017082, DOI: 10.1021/acscatal.8b01313
NAKAMURA Y ET AL., NUCLEIC ACIDS RES., vol. 27, 1999, pages 66 - 68
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453
P. PUIGBOE. GUZMANA. ROMEUS. GARCIA-VALLVE, NUCLEIC ACIDS RES., vol. 35, July 2007 (2007-07-01), pages W126 - W131
RADE LETICIA L. ET AL: "Dimer-assisted mechanism of (un)saturated fatty acid decarboxylation for alkene production", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 120, no. 22, 22 May 2023 (2023-05-22), XP093220658, ISSN: 0027-8424, Retrieved from the Internet <URL:https://www.pnas.org/doi/pdf/10.1073/pnas.2221483120> DOI: 10.1073/pnas.2221483120 *
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
SAMBROOKRUSSELL: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS
SHESTAKOV S V ET AL., PHOTOSYNTHESIS RESEARCH, vol. 73, 2002, pages 279 - 284
VAN DER WOUDE ET AL.: "Genetic engineering of Synechocystis PCC6803 for the photoautotrophic production of the sweetener erythritol", MICROB CELL FACT, vol. 15, 2016, pages 60
VON HEINE, G.: "Current protocols in molecular biology", 1987, GREEN PUBLISHING AND WILEY INTERSCIENCE
WANG ET AL.: "Metabolic engineering of Escherichia coli for the production of butyric acid at high titer and productivity", BIOTECHNOL BIOFUELS, vol. 12, 22 March 2019 (2019-03-22), pages 62
YUNUS ET AL.: "Synthetic metabolic pathways for photobiological conversion of CO into hydrocarbon fuel", METABOLIC ENGINEERING, vol. 49, September 2018 (2018-09-01), pages 201 - 211, XP085507112, DOI: 10.1016/j.ymben.2018.08.008
YUNUS: "Synthetic metabolic pathways for photobiological conversion of CO2 into hydrocarbon fuel", METABOLIC ENGINEERING, vol. 49, September 2018 (2018-09-01), pages 201 - 211, XP085507112, DOI: 10.1016/j.ymben.2018.08.008

Similar Documents

Publication Publication Date Title
US11142761B2 (en) Compositions and methods for rapid and dynamic flux control using synthetic metabolic valves
CN108779429B (zh) 单加氧酶的功能性表达和使用方法
Ko et al. Aldehyde dehydrogenase activity is important to the production of 3-hydroxypropionic acid from glycerol by recombinant Klebsiella pneumoniae
US9914947B2 (en) Biological production of organic compounds
US20170356016A1 (en) Modified microorganisms and methods for production of useful products
US20190194671A1 (en) Erythritol production in cyanobacteria
CN104651388B (zh) 一种高效合成乙烯的构建体及其构建方法和应用
Xie et al. Expressing 2-keto acid pathway enzymes significantly increases photosynthetic isobutanol production
WO2019246488A1 (fr) Compositions et procédés de production d&#39;acide pyruvique et produits apparentés en utilisant une commande dynamique du métabolisme
WO2014092562A1 (fr) Synthèse d&#39;acétoïne, de 2,3-butanediol et de 2-butanol par des cyanobactéries par expression hétérologue d&#39;une voie catabolique
DK3080243T3 (en) USE OF ENZYMES THAT CATALYZE PYRUVATH SYNTHESIS FROM FORMIATE AND ACETYL COA, AND BACTERIES THAT EXPRESS THIS
WO2017190056A1 (fr) Conversion de composés de 1-carbone en produits
Zhao et al. Formate as a supplementary substrate facilitates sugar metabolism and solvent production by Clostridium beijerinckii NCIMB 8052
JP2023505443A (ja) 組換え微生物からエチレンを生産するための方法及び組成物
WO2025032068A1 (fr) Production de propylène dans des cyanobactéries
CN102978229B (zh) 蓝藻整合表达载体及其应用
Lin et al. Rewiring Cupriavidus necator for Enhanced Polyhydroxybutyrate Production via Genetic Toolkits and Feeding Strategy
WO2017210381A1 (fr) Bioconversion de matières premières de 1-carbone en produits chimiques et en combustibles
CA2948382C (fr) Compositions et procedes pour une regulation de flux rapide et dynamique au moyen de soupapes metaboliques synthetiques
JP2017192369A (ja) 組換え細胞、並びに、イソ酪酸の生産方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24754269

Country of ref document: EP

Kind code of ref document: A1